InfuSystem Holdings to Release Q2 2026 Earnings and Host Investor Call on August 4

Schedule for Earnings Release and Disclosure

InfuSystem Holdings will make its Q2 2026 financial results public on Tuesday, August 4, 2026, before the start of regular trading hours. This timing enables investors and market participants to analyze the company’s quarterly performance ahead of market open, facilitating informed trading decisions at the start of the day. Releasing earnings pre-market is a common practice among publicly traded companies to provide equal access to financial data across all investor groups.

The disclosure will encompass financial performance and key metrics for the second quarter. By publishing results before market open, InfuSystem Holdings ensures institutional investors, retail shareholders, and analysts receive the information simultaneously, minimizing information asymmetry in the market.

Investor Conference Call Details

Following the earnings release, InfuSystem Holdings will host a live conference call on August 4, 2026, at 9:00 a.m. Eastern Time. This call offers shareholders and interested parties the chance to hear directly from company management about the quarterly results and to ask questions. Typically, senior executives provide remarks followed by a Q&A session with analysts and investors.

Scheduling the call on the same day as the earnings release allows participants to review the financial statements before engaging with management commentary. This integrated communication approach helps investors gain a comprehensive understanding of the company’s operational and financial performance for the reported period.

About InfuSystem Holdings

InfuSystem Holdings, Inc., incorporated in Delaware with headquarters in Rochester Hills, Michigan, trades on NYSE American LLC under the ticker INFU. Operating in the medical technology sector, the company regularly fulfills public disclosure obligations through SEC filings and periodic announcements to shareholders and the investment community.

As a publicly listed company, InfuSystem Holdings adheres to quarterly reporting and investor communication standards mandated by securities regulations. Its commitment to scheduled earnings releases and investor calls reflects its dedication to transparent communication regarding financial results and business operations.

Compliance with Regulation Fair Disclosure

The July 28, 2026 announcement complies with Regulation Fair Disclosure (FD), an SEC rule ensuring that material information is disseminated simultaneously to all investors. The information was provided via press release rather than a formal filing, serving informational purposes without triggering certain securities law liabilities.

The company clarified that this disclosure under Item 7.01 is not considered "filed" for Section 18 of the Securities Exchange Act of 1934 purposes, nor incorporated by reference into other filings under the Securities Act of 1933 or the Exchange Act. This standard practice applies to routine announcements such as earnings releases and conference calls.

Press Release and Documentation

InfuSystem Holdings included its July 28, 2026 press release as Exhibit 99.1 in its disclosure, formally notifying the market of the upcoming earnings release and conference call. This ensures consistent and identical information is available to all market participants.

The filing also contains an interactive data file in Inline XBRL format, the SEC’s standard electronic submission format for regulatory documents. This facilitates automated data processing and analysis by investors, regulators, and financial data providers.

Investor Action Timeline

Stakeholders interested in InfuSystem Holdings’ Q2 2026 results should note Tuesday, August 4, 2026, as the key date. Financial results will be available before market open, allowing review prior to trading. The 9:00 a.m. Eastern Time conference call will follow, providing an opportunity for direct engagement with management.

This schedule offers investors ample time to analyze information, form opinions, and make investment decisions based on the disclosed financial performance. The timing promotes transparency and market efficiency by ensuring broad, simultaneous access to material quarterly results.

Executive Certification and Filing Authority

The disclosure was signed by Carrie Lachance, Chief Executive Officer and Director of InfuSystem Holdings. Her signature certifies that the document was authorized and executed in compliance with SEC requirements, assuring the disclosure’s authenticity and regulatory adherence.

Signing on July 28, 2026—the announcement date—reflects the prompt processing and filing of the earnings schedule. The involvement of a senior corporate officer underscores the disclosure’s importance.

Corporate Filing and Registration Information

InfuSystem Holdings’ SEC filings are maintained under Commission File Number 001-35020 and IRS Employer Identification Number 20-3341405. The company’s common stock, with a par value of $0.0001 per share, trades on NYSE American LLC under the symbol INFU. These identifiers assist investors and regulators in locating official filings and regulatory submissions.

The company is not classified as an emerging growth company under SEC regulations, meaning it complies fully with public company reporting requirements without extended transition periods available to smaller companies. Complete regulatory filings and disclosures are accessible via the SEC’s EDGAR database.

Investor Considerations Post-Announcement

Investors should prepare for InfuSystem Holdings’ Q2 2026 earnings release by reviewing recent financial reports and understanding the company’s key operational and financial metrics. Comparing current results to prior periods and analyst forecasts will provide valuable context.

During the August 4, 2026 conference call at 9:00 a.m. Eastern Time, investors will likely focus on management commentary about revenue trends, operating margins, capital expenditures, and future guidance. The Q&A session will offer direct insights into management’s views on competitive dynamics, market opportunities, and operational challenges.